
VION PHARMACEUTICALS, INC. (Nasdaq: VION) announced the start of an investigator-sponsored Phase I/II clinical trial of its lead anticancer agent Cloretazine(R) (VNP40101M) in combination with cytarabine in elderly patients with previously untreated acute myelogenous leukemia (AML) and high-risk myelodysplastic syndromes (MDS).
Click here for full Story http://www.medicalnewstoday.com/articles/106848.php |